Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

No April Fool's Joke: MannKind's Critical Vote

By Dave Williamson - Mar 30, 2014 at 8:12AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

MannKind's got a big vote coming up, and a key drug with a future in jeopardy.

Shares of MannKind ( MNKD ) took more than a 5% haircut on Friday as briefing documents came out for its upcoming FDA advisory committee meeting on Tuesday. The documents are a mixed bag, which should make for a very interesting debate in Tuesday's meeting. The drug, an inhaled form of insulin called Afrezza, had efficacy that looked good for type 2 diabetes, but wasn't as convincing on type 1. There are also potential safety concerns, including an imbalance of lung cancer cases in the drug's cohort which could be associated with inhaled insulin as a drug class. A similar small imbalance, dogged a predecessor product, Pfizer's ( PFE 2.32% ) Exhubera.

There is a great deal of investor optimism around the sales potential of Afrezza, as an alternative to needles. Investors see Novo Nordisk's ( NVO 0.41% ) Novalog and Eli Lilly's ( LLY -0.93% ) Humalog's roughly $1.5 billion each in U.S. sales last year and think it can capture a significant portion, possibly as much as a quarter of that market. However, MannKind's high valuation and significant downside risk if Afrezza is rejected, makes this a stock even serious biotech investors with a Mount Everest-high risk tolerance should probably watch from sidelines. 

In this video, Motley Fool health-care analyst David Williamson looks at MannKind today, ahead of the advisory committee's meeting. The vote could greatly affect the outcome of an FDA decision. David discusses the potential for the drug on the market, and how MannKind would be affected by an FDA rejection.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MannKind Corporation Stock Quote
MannKind Corporation
Pfizer Inc. Stock Quote
Pfizer Inc.
$54.27 (2.32%) $1.23
Novo Nordisk A/S Stock Quote
Novo Nordisk A/S
$107.08 (0.41%) $0.44
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$245.58 (-0.93%) $-2.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.